BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Other Financing Activities
Financing cash flows not reported separately.
BioAge Labs, Inc.NASDAQ: BIOA
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities turns negative
Q1 FY2026 other financing activities was -$807K, compared with $0 a year earlier. Trailing-twelve-month other financing activities was -$1.21M. Over 3 fiscal years it compounded at +107.1% a year.
Context
- Other financing activities amounted to 4.4% of revenue in FY2025.
- Other financing activities grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other financing activities holds near -$807K or moves back toward the trailing-twelve-month quarterly average of -$301.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (400K) USD
- Year-over-year change
- +91.0%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (400K) | +91.0% |
| FY2024 | 2024-12-31 | (4.42M) | -7391.5% |
| FY2023 | 2023-12-31 | (59K) | -31.1% |
| FY2022 | 2022-12-31 | (45K) | — |
Other Financing Activities vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -100.6% is the 8th highest of 9, against a peer median of +94.8%.
- Other financing activities amounts to 11.7% of revenue for BIOA, versus a peer median of 6.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $91.94M USD | -292.0% | — | 4560.7% | |
| LTM Mar 2026 | CA$28.63M CAD | +79.4% | — | 9.2% | |
| LTM Mar 2026 | $6.05M USD | +5.3% | — | — | |
| LTM Mar 2026 | $3.56M USD | -43.4% | — | — | |
| LTM Mar 2026 | $2.89M USD | +200.7% | — | 7.5% | |
| LTM Mar 2026 | $2.38M USD | +110.2% | +56.2% | 5.7% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $1.21M USD | -100.6% | +107.1% | 11.7% |
| LTM Mar 2026 | $1.05M USD | +116.9% | — | — | |
| LTM Mar 2026 | CA$1.01M CAD | +515.2% | -88.3% | 0.3% | |
| LTM Mar 2026 | $51K USD | — | — | 0.0% | |
| Peer median (excluding BIOA) | — | +94.8% | -16.0% | 6.6% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.